Experimental in vivo model to evaluate the impact of Cernitin™ on pain response on induced chronic bladder inflammation

References

• Lamvu G, Carrillo J, Ouyang C, et al. Chronic pelvic pain in women: a review. J Am Med Assoc. 2021;325(23):2381–2391.
   PubMed Web of Science ®Google Scholar
• Augé C, Gamé X, Vergnolle N, et al. Characterization and validation of a chronic model of cyclophosphamide-Induced interstitial cystitis/bladder pain syndrome in rats. Front Pharmacol. 2020;11(August):1305–1311.
   PubMedGoogle Scholar
• Togo Y, Ichioka D, Miyazaki J, et al. Oral administration of cernitin pollen extract (Cernilton®) for 30 days might be useful to avoid unnecessary biopsy in prostate biopsy candidates: a preliminary study. Int J Urol. 2018;25(5):479–485.
   PubMed Web of Science ®Google Scholar
• Wagenlehner FME, Bschleipfer T, Pilatz A, et al. Pollen extract for chronic prostatitis-chronic pelvic pain syndrome. Urol Clin North Am. 2011;38(3):285–292.
   PubMed Web of Science ®Google Scholar
• Chabot S, Dizeyi N, Ramnemark L, et al. Impact of CernitinTM on induced chronic prostatitis in animal model for understanding management of lower urinary tract symptoms. Phytomedicine Plus. 2021;1(4):100057.
   Google Scholar
• Iwamura H, Koie T, Soma O, et al. Eviprostat has an identical effect compared to pollen extract (Cernilton) in patients with chronic prostatitis/chronic pelvic pain syndrome: a randomized, prospective study. BMC Urol. 2015;15(1):5–10.
   PubMedGoogle Scholar
• Lu CF, Meng XH, Li HB, et al. Effect of phellodendron chinense extract on carrageenan-induced chronic prostatitis in rats. Trop J Pharm Res. 2015;14(2):257–262.
   Web of Science ®Google Scholar
• Talpur N, Echard B, Bagchi D, et al. Comparison of Saw Palmetto (extract and whole berry) and Cernitin on prostate growth in rats. Mol Cell Biochem. 2003;250(1/2):21–26.
   PubMed Web of Science ®Google Scholar
• Wagenlehner FME, Schneider H, Ludwig M, et al. A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis-chronic pelvic pain syndrome: a multicentre, randomised, prospective, double-blind, placebo-controlled phase 3 study. Eur Urol. 2009;56(3):544–551.
   PubMed Web of Science ®Google Scholar
• Shoskes DA, Nickel JC, Rackley RR, et al. Clinical phenotyping in chronic prostatitis/chronic pelvic pain syndrome and interstitial cystitis: a management strategy for urologic chronic pelvic pain syndromes. Prostate Cancer Prostatic Dis. 2009;12(2):177–183.
   PubMed Web of Science ®Google Scholar
• Ayhanci A, Yaman S, Sahinturk V, et al. Protective effect of seleno-L-methionine on cyclophosphamide-induced urinary bladder toxicity in rats. Biol Trace Elem Res. 2010;134(1):98–108.
   PubMed Web of Science ®Google Scholar
• Guo M, Chang P, Hauke E, et al. Expression and function of chemokines CXCL9-11 in micturition pathways in cyclophosphamide (CYP)-induced cystitis and somatic sensitivity in mice. Front Syst Neurosci. 2018;12(April):9–16.
   PubMedGoogle Scholar
• Tooke K, Girard B, Vizzard MA. Functional effects of blocking VEGF/VEGFR2 signaling in the rat urinary bladder in acute and chronic CYP-induced cystitis. Am J Physiol Renal Physiol. 2019;317(7):F43–F51.
   PubMedGoogle Scholar
• Ozyuvali E, Yaman T, Kosem B, et al. Protective effect of intravesical platelet-rich plasma on hemorrhagic cystitis. CIM. 2016;39(6):116–121.
   Google Scholar
• Vera PL, Iczkowski KA, Wang X, et al. Cyclophosphamide-induced cystitis increases bladder CXCR4 expression and CXCR4-macrophage migration inhibitory factor association. PLoS One. 2008;3(12):e3898.
   PubMed Web of Science ®Google Scholar
• Malley SE, Vizzard MA. Changes in urinary bladder cytokine mRNA and protein after cyclophosphamide-induced cystitis. Physiol Genomics. 2002;9(1):5–13.
   PubMed Web of Science ®Google Scholar
• Mitchell JA, Warner TD. Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br J Pharmacol. 1999;128(6):1121–1132.
   PubMed Web of Science ®Google Scholar
• Hu VY, Malley S, Dattilio A, et al. COX-2 and prostanoid expression in micturition pathways after cyclophosphamide-induced cystitis in the rat. Am J Physiol Regul Integr Comp Physiol. 2003;284(2):53–52.
   Web of Science ®Google Scholar
• Ricciotti E, Fitzgerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol. 2011;31(5):986–1000.
   PubMed Web of Science ®Google Scholar
• Hannan TJ, Roberts PL, Riehl TE, et al. Inhibition of cyclooxygenase-2 prevents chronic and recurrent cystitis. EBioMedicine. 2014;1(1):46–57.
   PubMed Web of Science ®Google Scholar
• Augé C, Basso L, Blanpied C, et al. Pain management in a model of interstitial cystitis/bladder pain syndrome by a vaccinal strategy. Front Pain Res. 2021;2(March):1–8.
   Google Scholar
• Augé C, Chene G, Dubourdeau M, et al. Relevance of the cyclophosphamide-induced cystitis model for pharmacological studies targeting inflammation and pain of the bladder. Eur J Pharmacol. 2013;707(1-3):32–40.
   PubMed Web of Science ®Google Scholar
• Birder L, Andersson KE. Animal modelling of interstitial cystitis/bladder pain syndrome. Int Neurourol J. 2018;22(Suppl 1):S3–S9.
   PubMedGoogle Scholar
• Bjorling DE, Wang ZY, Bushman W. Models of inflammation of the lower urinary tract. Neurourol Urodyn. 2011;30(5):673–682.
   PubMed Web of Science ®Google Scholar
• Meotti FC, Forner S, Lima-Garcia JF, et al. Antagonism of the transient receptor potential ankyrin 1 (TRPA1) attenuates hyperalgesia and urinary bladder overactivity in cyclophosphamide-induced haemorrhagic cystitis. Chem Biol Interact. 2013;203(2):440–447.
   PubMed Web of Science ®Google Scholar
• Lee JW, Han DY, Jeong HJ. Bladder pain syndrome treated with triple therapy with gabapentin, amitriptyline, and a nonsteroidal anti-inflammatory drug. Int Neurourol J. 2010;14(4):256–260.
   PubMedGoogle Scholar
• White FA, Feldman P, Miller RJ. Chemokine signaling and the management of neuropathic pain. Mol Interv. 2009;9(4):188–195.
   PubMedGoogle Scholar
• Lv J, Huang Y, Zhu S, et al. MCP-1-induced histamine release from mast cells is associated with development of interstitial cystitis/bladder pain syndrome in rat models. Mediators Inflamm. 2012;2012:358184.
   PubMed Web of Science ®Google Scholar
• Xu S, Wang X, Wang Y, et al. Transgenic mice expressing MCP-1 by the urothelium demonstrate bladder hypersensitivity, pelvic pain and voiding dysfunction: a multidisciplinary approach to the study of chronic pelvic pain research network animal model study. PLoS One. 2016;11(9):e0163829.
   PubMed Web of Science ®Google Scholar
• Kiyokazu N, Ikuko K, Masayasu K. Effects of pollen-extract components, diamines and derivatives of feruloylputrescine on isolated bladder and urethral smooth muscles of mice. Jpn J Pharmacol. 1990;53(2):157–164.
   PubMedGoogle Scholar
• Arms L, Vizzard MA. Neuropeptides in lower urinary tract function. Handb Exp Pharmacol. 2011;202(202):395–423.
   Google Scholar
• Girard BM, Wolf-Johnston A, Braas KM, et al. PACAP-mediated ATP release from rat urothelium and regulation of PACAP/VIP and receptor mRNA in micturition pathways after cyclophosphamide (CYP)-induced cystitis. J Mol Neurosci. 2008;36(1-3):310–320.
   PubMed Web of Science ®Google Scholar